AGC Biologics Strengthens Leadership with Appointment of Dr. Christoph Winterhalter as Chief Business Officer

AGC Biologics has announced the appointment of Dr. Christoph Winterhalter as its new Chief Business Officer, marking a significant step in strengthening its leadership team. With over 30 years of experience in the life science industry, Winterhalter is tasked with overseeing corporate strategy, business development, and global marketing for the company's Contract Development and Manufacturing Organization (CDMO) network. His extensive background includes developing strategies for sustainable business growth, leading global teams, and establishing strategic partnerships with major pharmaceutical companies.

Prior to this role, Winterhalter served as the Senior Vice President of Business Development for Europe, the Middle East, and Africa at AGC Biologics, where he has been instrumental in the company's growth since joining in 2018. His previous experience also includes a tenure at Rentschler Biopharma, where he significantly contributed to tripling the company's sales through strategic alliances and global sales strategies.

Patricio Massera, CEO of AGC Biologics, praised Winterhalter's unique blend of technical expertise and business acumen, emphasizing his potential to drive the company's growth and enhance its global operations. Winterhalter expressed his enthusiasm for his new role, highlighting his commitment to advancing AGC Biologics' mission of enabling life-changing therapies for patients worldwide. This appointment underscores AGC Biologics' commitment to leadership and innovation in the biopharmaceutical industry, promising to bolster its position as a leading CDMO.